# Cymabay Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cymabay-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Newark, US
- Website: www.cymabay.com
- Total disclosed funding: $86M
- Latest round: Series D (Apr 12, 2007)
- Investors on record: 16

## About

Cymabay Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for liver and metabolic disease. It seeks to address significant unmet medical needs through its specialized treatment options.Founded in 1991 and headquartered in Newark, US, Cymabay Therapeutics, Inc. specializes in developing treatments for liver and metabolic diseases. The company has undergone a series of funding rounds, with the most recent being a TRADE SALE in July 2014, raising USD 4,300.00 mn. The CEO of the company is Sujal Shah.Cymabay Therapeutics focuses on developing innovative therapeutics for liver diseases. Its offerings include various clinical-stage candidates aimed at addressing unmet needs in metabolic disorders. The company is engaged in advancing its drug candidates through clinical trials to assess their efficacy and safety in treating liver and metabolic diseases.In 2018, Cymabay Therapeutics recorded a revenue of USD 0, with an EBITDA of USD -92,401,000 for the same year. The revenue model is primarily based on the potential commercialization of its therapeutic products once they reach the market.Cymabay Therapeutics plans to utilize the funding from its most recent deal in July 2014 to accelerate the development of its four clinical-stage candidates. The company aims to launch new products targeting liver and metabolic diseases, with specific timelines for clinical trial phases yet to be disclosed. Additionally, Cymabay is exploring opportunities for expansion into new markets, although specific geographic regions have not been identified in the current strategy.

## Funding rounds

- Series D, Apr 12, 2007, $32M — Alta Partners, T Rowe Price, VantagePoint Capital, Versant Ventures, Venrock, AllianceBernstein, Johnson & Johnson Innovation, Novo Holdings, Bay City Capital, Lombard Odier Asset Management, MPM BioImpact, KBC Private Equity, Biotechnology Turnaround Fund, Deerfield Management, Birchmere
- Series C, Aug 30, 2006, $10M — Alta Partners, VantagePoint Capital, Versant Ventures, Bay City Capital, Biotechnology Turnaround Fund
- Series B, Nov 19, 2004, $44M — Alta Partners, VantagePoint Capital, Versant Ventures, Venrock, Novo Holdings, Bay City Capital, KBC Bank, Birchmere

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series B, Series C, Series D
- VantagePoint Capital (https://capitalatlas.ai/funds/vantagepoint-capital) — Series B, Series C, Series D
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series B, Series C, Series D
- Venrock (https://capitalatlas.ai/funds/venrock) — Series B, Series D
- Novo Holdings — Series B, Series D
- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series B, Series C, Series D
- KBC Bank — Series B
- Birchmere (https://capitalatlas.ai/funds/birchmere) — Series B, Series D
- Biotechnology Turnaround Fund — Series C, Series D
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series D
- AllianceBernstein (https://capitalatlas.ai/funds/alliancebernstein) — Series D
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series D
- Lombard Odier Asset Management — Series D
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series D
- KBC Private Equity (https://capitalatlas.ai/funds/kbc-private-equity) — Series D
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series D